September 13 -- or 9/13 -- is a reminder of a disparity in federal law that continues to shape which new medicines receive investment. Under the Inflation Reduction Act (IRA), small molecule drugs become eligible for Medicare price setting just nine years after FDA approval, compared with 13 years for biologics. That four-year difference, known as the "pill penalty," gives investors an incentive to favor biologics over small molecule medicines. Drug development is a long an

WASHINGTON (August 7) – Yesterday, Senators Pete Ricketts (R-NE) and Elissa Slotkin (D-MI) introduced the Biotech Investment National Security Act (BINSA). The legislation would establish new restrictions on certain U.S. biotechnology investments and partnerships involving China as lawmakers seek to address national security concerns. Incubate's executive director, John Stanford, issued the following statement: "China's rise in biotechnology is real, and the United States sho